PDL1 on Tumor
Marrone, KA: Cancernetork.com
Kinetics of Appearance of irAEs With Checkpoint Blockade
Data from pts receiving anti–PD-1 antibodies q2w for ≥ 3 yrs show most irAEs occur by Wk 24 (6 mos)
Toxicities with PD-1/PD-L1 agents may take longer to resolve than with ipilimumab, so long-term surveillance is recommended
Weber JS, et al. J Clin Oncol. 2012;30:2691-2697.
Weber JS, et al. J Clin Oncol. 2015;[Epub ahead of print].
来自接受抗pd-1抗体治疗患者（q2w）≥3年的资料显示，免疫相关不良反应最多发生在24周（6个月）pd-1/pd-l1药物的毒性比ipilmumab更长时间才能消除，因此建议进行长期监测
Management of Drug-Related AEs
The majority of both Anti CTLA 4 and anti PD 1- related AEs to date have been reversible and manageable by delaying study drug ± administration of corticosteroids; other immunosuppressants may also be needed
The following categories of AEs, requiring greater vigilance and early intervention:
Pulmonary
Hepatic
Renal
GI
Endocrine
Neurological
Skin
|
|
